FLGT
Fulgent Genetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$20.33
+1.14%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$20.19
From 52W high−34.10%
Volume160737.00
Market cap$559.39M
P/E (TTM)—
P/S (TTM)1.7x
Div yield—
Key dataOct 20, 2026
Open
$20.19
From 52W high
−34.10%
Volume
160737.00
Market cap
$559.39M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.7x
P/E (TTM)
—
RSI (14)
47.9
MomentumView details →
1D Return
+1.14%
YTD Return
−21.30%
SummaryUpdated Jun 1, 2026
Fulgent Genetics, Inc. (NASDAQ:FLGT) is a California-based medical diagnostics and genetic testing company founded in 2011 and headquartered in Temple City, California. The company went public in September 2016 and has evolved from a COVID-19 testing provider during the pandemic to a comprehensive genetic testing and precision medicine company. Today, Fulgent operates three main business segments: precision diagnostics, anatomic pathology, and biopharma services, while also developing therapeutic drugs through its Fulgent Pharma division.
Similar companies
Latest newsMore news →
Fulgent Genetics announced that management will host an investment-community conference call to discuss the third-quarter 2026 results.6d agoFulgent Genetics announced that it will release its third-quarter 2026 financial results after the market closes on November 5, 2026.6d agoFulgent Genetics, Inc. reported a quarterly loss of $0.58 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.46 per share, compared to earnings of $0.07 per share a year ago.82d ago